GENOMIC VISION

Promising Results from the New Telomere Length Assay (TLA) in the Scope of Development of Cancer Therapies - Seite 2

Associate Professor Hilda Pickett, Children Medical Research Institute (CMRI), added: “We greatly appreciate our partnership with Genomic Vision. The collaboration has existed for about one year during which we have been progressing quickly on TLA to detect and analyze telomeres in cells. Using TLA, it is possible to discriminate individual telomere lengths, and measure the precise distribution of telomere lengths in a variety of samples, including mice and human cells. TLA can measure telomere lengths <1 kb and >80 kb, enabling us to have a clearer understanding of the association between telomere length and disease.

In my laboratory, we are investigating how telomere length contributes to cell proliferation and human health, and how telomere maintenance mechanisms become activated in cancer cells. TLA provides a new way to examine telomere length, which can be applied to further understand the underlying mechanisms of telomere dysfunction and telomere length regulation.”

***

ABOUT GENOMIC VISION

Genomic Vision is a biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes.

Genomic Vision proprietary molecular tools provide robust quantitative measurements that are needed to enable high confidence characterization of DNA alteration in the genome. These tools are currently use for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases.

Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV - ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document dated March 28, 2017, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.